Astellas Pharma accelerates clinical trial insights with unified data platform

Astellas Pharma, a Tokyo-based global pharmaceutical company, aimed to modernize and streamline its R&D data processing to enhance clinical trial outcomes. Historically, manual data curation from multiple disconnected sources delayed key insights and decision-making across its portfolio of trials. In partnership with PwC and Microsoft, Astellas developed an integrated data platform on Microsoft Azure, harmonizing data from 48 disparate source systems into a central, real-time repository. This transformation empowered stakeholders with self-serve dashboards, instant customizable reporting, and advanced analytics, significantly speeding up processes previously taking months. Executives gained an improved ability to detect issues like low participant recruitment or study delays, and quickly act on these insights. The scalable Azure-based solution delivered new operational efficiencies and now supports predictive and prescriptive analytics capabilities to further optimize clinical operations and patient outcomes. Astellas initiated the project to address outdated, manual, and error-prone data curation in clinical trials. Disparate, siloed internal and external data systems made important insights slow to surface. By working with PwC and Microsoft, Astellas brought 48 independent data sources together into one dependable platform for actionable insights and real-time analytics, fundamentally transforming its R&D oversight process.